Abstract 693P
Background
PD-1/PD-L1 monoclonal antibodies have revolutionised the landscape of cancer treatment. Nonetheless, some PD-L1+ patients do not respond to or become resistant to such therapy. The elevated expression of PD-L1 in tumours makes it an attractive target for ADC development, which could potentially alter the treatment for PD-1/PD-L1 inhibitor refractory/resistant (R/R) cancers.
Methods
HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8. Our innovative linker-payload is activated preferentially in the tumour microenvironment, enabling its tumour-specific release of the toxin without needing internalisation of the ADC. Toxin release in PD-L1+ cancer cells is efficient and tumour-specific, minimizing damage to normal cells and reducing systemic toxicity from non-specific toxin release in periphery. HLX43 was examined in antigen binding, internalisation, and plasma stability assays; efficacy studies were performed in multiple CDX and PDX models.
Results
HLX43 has been shown to have similar affinity and internalisation rates as the parental antibody. It was stable in the plasma of rats and cynomolgus monkeys. In in vivo efficacy studies, HLX43 induced tumour regression in multiple PD-L+ CDX and PDX models, and was well tolerated across all dosing groups. Weekly administration of HLX43 8 mg/kg for three times significantly reduced tumours in the MDA-MB-231 model without causing weight loss. HLX43 exhibited superior anticancer efficacy compared to anti-PD-L1-GGFG-Dxd at equal doses in all models tested, including those with low PD-L1 levels, high heterogeneity, and non-responsiveness to PD-1/PD-L1 inhibitors. Preliminary toxicity assessments demonstrated good tolerability of HLX43 in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates. GLP toxicology studies will explore a higher dose at 20 mg/kg.
Conclusions
HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.
Clinical trial identification
Editorial acknowledgement
Shiqi Zhong of Shanghai Henlius Biotech, Inc.
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
Y. Shan, R. Liu, G. Song, H. Song, J. Jiang, C. Jia, Y. Chen, X. Yuan, Z. Hou, X. Wang, X. Hou, Y. Shen, C. Hu, H. Wei, Q. Wang, J. Zhu: Financial Interests, Personal, Full or part-time Employment: Shanghai Henlius Biotech, Inc.
Resources from the same session
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17
117P - Genomic landscape of biliary tract cancers from India show distinct geographic variation
Presenter: Nitesh Rohatgi
Session: Poster session 17
118P - Artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker for anti-PD-1 in advanced biliary tract cancer (BTC)
Presenter: Yeonghak Bang
Session: Poster session 17
119P - Management of biliary tract cancers in older patients: A French multicenter cohort study
Presenter: Marine Valery
Session: Poster session 17
120P - Management of biliary tract cancers in early onset patients: A French multicenter real-life study from the ACABI-PRONOBIL cohort
Presenter: Antoine Lebeaud
Session: Poster session 17
121P - PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium
Presenter: Blandine Delaunay
Session: Poster session 17
122P - Largest examination of cholangiocarcinoma (CCA) patients (pts) treated with novel targeted therapies after extended molecular profiling on liquid biopsies
Presenter: Umair Mahmood
Session: Poster session 17
123P - Artificial intelligence (AI)-powered analysis of human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TILs) in advanced biliary tract cancer (BTC)
Presenter: Gwangil Kim
Session: Poster session 17
124P - Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Maria Bensi
Session: Poster session 17
125P - Real-world treatment patterns in patients with biliary tract cancer (BTC): Retrospective chart review survey in Europe (GARNET-2)
Presenter: John Bridgewater
Session: Poster session 17